<DOC>
	<DOCNO>NCT02401373</DOCNO>
	<brief_summary>This single center , open , dose-escalation phase 1 clinical trial . This study determine safety side-effect profile , immunogenicity investigational Ad5-EBOV vaccine Healthy Adult Africans age 18-60 year China .</brief_summary>
	<brief_title>A Phase I Trial Evaluate Ad5-EBOV Healthy Adult Africans China .</brief_title>
	<detailed_description>This single center , open , dose-escalation clinical trial . According Chinese guideline vaccine clinical trial , sample size phase 1 clinical trial least 20 . In study , total 60 participant included.30 participant firstly recruit assigned receive low dose Ad5-EBOV . After safety low dose vaccination confirm , another 30 participant recruit assigned receive high dose Ad5-EBOV . The whole follow-up period participant 28 day .</detailed_description>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Hemorrhagic Fever , Ebola</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 18 60 year . African China . Able understand content inform consent willing sign inform consent Able willing complete seclude study process whole study followup period ( 1 month ) . A body mass index ( BMI ) 18.535.0 kg/m2 Hemoglobin ≥110g/L female , ≥120g/L male . White blood cell ( WBC ) 4.010.0×109 cells/L Total lymphocyte Count 0.84.5×109 cells/L Platelets 100300×109 cells/L Alanine aminotransferase ( ALT ) 040U/L Serum creatinine 44106μmol/L Active partial thromboplastin time ( APTT ) 2040 second Prothrombin time ( PT ) 1014 second Negative HIV diagnostic blood test Axillary temperature ≤37.0°C day enrollment General good health establish medical history physical examination . Family history seizure , epilepsy , brain mental disease Participant medical history following : allergic history vaccination drug , allergic ingredient Ad5EBOV , mannitol . Woman pregnant , breastfeed positive βHCG ( human chorionic gonadotropin ) pregnancy test ( urine ) day enrollment , become pregnant next 6 month Any acute fever disease infection last 7 day Major congenital defect wellcontrolled chronic illness , asthma , diabetes , thyroid disease Hereditary angioneurotic edema acquire angioneurotic edema Urticaria last one year Asplenia functional asplenia Platelet disorder bleed disorder may cause injection contraindication Faint sight blood needle . Prior administration immunodepressant corticosteroid , antianaphylaxis treatment , cytotoxic treatment last 6 month Prior administration blood product last 4 month Prior administration research medicine last 1 month Prior administration attenuate vaccine last 1 month Prior administration inactivate vaccine last 14 day Current antituberculosis prophylaxis therapy Any condition opinion investigator may interfere evaluation study objective</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Vaccines</keyword>
	<keyword>Ebola Virus Disease</keyword>
</DOC>